38 Documents

Publication numbers	Title	Current assignees
US20180066036 A1	Single-chain cd40-receptor agonist proteins	APOGENIX
EP2310509 A1	Moléculas de tnfsf em cadeia simples	APOGENIX
EP2484691 A1	Tnf superfamily collectin fusion proteins	APOGENIX
WO201772080 A1	Single-chain tl1a receptor agonist proteins	APOGENIX
WO201768192 A1	Single-chain cd27-receptor agonist proteins	APOGENIX
WO201768183 A1	Single-chain cd137-receptor agonist proteins	APOGENIX
WO201768181 A1	Single-chain ox40-receptor agonist proteins	APOGENIX
WO201768180 A1	Single-chain light receptor agonist proteins	APOGENIX
WO201768185 A1	Single-chain gitr-receptor agonist proteins	APOGENIX
WO201751002 A1	Anti-cd95l antibody	APOGENIX
WO201709429 A1	Method of predicting the responsiveness of a cancer disease to treatment	APOGENIX
JP2016210791 A	Fusion proteins forming trimers	APOGENIX
BR112017023646 A1	Proteã**nas agonistas de receptor de cd40 de cadeia simples	APOGENIX
EP3010753 A1	Device for adjusting the seat inclination of a motor vehicle seat	JOHNSON CONTROLS COMPONENTS
BR112015027249 A1	Método de diagnóstico de câncer	APOGENIX
EP3161003 A2	Combination of cd95/cd95l inhibition and cancer immunotherapy	APOGENIX
EP3137909 A1	Diagnostic anti-cd95l antibody	APOGENIX
BR112016024515 A1	Proteínas do agonista do receptor trail de cadeia única	ABBVIE, ...
JP2015143270 A	Fusion proteins forming trimers	APOGENIX
EP3094744 A1	Method of predicting the responsiveness of a cancer disease to treatment on the basis of dna methylation	APOGENIX
JP2014218510 A	Fusion proteins forming trimers	APOGENIX
BR112015000732 A1	Composição compreendendo uma mistura de isoformas de cd95-fc	APOGENIX
BR112015000998 A1	Inibidores da via de sinalização cd95 para tratamento de mds e seus usos	APOGENIX
AU2013203061 A1	TNF superfamily collectin fusion proteins	APOGENIX
US20100111969 A1	Il-4 receptor and il-13 as prognostic markers for colon and pancreas tumors	APOGENIX
EP2310409 A2	Multimeric TNF receptors	APOGENIX
EP2271674 A2	Binding agents directed against il-4 receptor for the treatment of tumors, inflammatory and immunological	APOGENIX

Publication numbers	Title	Current assignees
	disorders	
EP2382236 A1	Fusion proteins forming trimers	APOGENIX
EP2181877 A1	Industrial truck comprising a system for detecting spinning or locking of the drive wheel	BT PRODUCTS
US20090196868 A1	Methods and compositions for preventing radiation-induced pneumonitis	APOGENIX
WO2008101671 A2	Il-4 fc fusion proteins	APOGENIX
EP2049147 A2	Human il-4 muteins in combination with chemotherapeutics or pro-apoptotic agents in cancer therapy	APOGENIX
EP2009022 A1	Trimeric death ligands with enhanced activity (tenascin)	APOGENIX
BR200713484 A2	Expressão diferencial de citocina em câncer humano	APOGENIX
EP2004691 A1	Antibody specific for human il-4 for the treament of cancer	APOGENIX
EP1894940 A1	Tnf superfamily fusion proteins	APOGENIX
EP1805299 A1	Method for the purification and amplification of tumoral stem cells	APOGENIX
EP1606319 A2	Proteínas de fusão de fc melhoradas	APOGENIX, ...

Single-chain cd40-receptor agonist proteins
US20180066036 A1

Current assignees
APOGENIX*

Inventors
HILL OLIVER
GIEFFERS CHRISTIAN
THIEMANN MEINOLF
SCHNYDER TIM

Priority data including date
2015US-62156813 2015-05-04
2016WO-EP59983 2016-05-04
2017US-15795020 2017-10-26

IPC - International classification
C07K-014/705*

CPC - Cooperative classification

A61K-038/00	C07K-014/705/75*	C07K-2319/02
C07K-2319/22	C07K-2319/30	C07K-2319/32
C07K-2319/35	C07K-2319/74	

Family

US20180066036	A1	2018-03-08	

(US20180066036)
Provided herein are specific CD40 receptor agonist proteins, nucleic acids encoding the same, and methods of treating a subject having a CD40L-associated disease or disorder.The CD40 receptor agonist proteins provided herein comprise three soluble CD40L domains and an Fc fragment.The CD40 receptor agonist proteins are substantially non-aggregating and suitable for therapeutic, diagnostic and/or research applications.



Images



Moléculas de tnfsf em cadeia simples
EP2310509 A1

Current assignees

APOGENIX*

APOGENIX* GESELLSCHAFT MITT BESHLÃ¤CKTEL HUFTUNG APOGENIX*

APOGENIX*US

Inventors

HILL OLIVER

GIEFFERS CHRISTIAN

THIEMANN MEINOLF

Priority data including date

2008EP-0013112 2008-07-21
2009CA-2731388 2009-07-18
2009EP-0780803 2009-07-18
2009WO-EP59269 2009-07-18
2011US-13055109 2011-03-10
2013EP-0152482 2009-07-18
2013US-13902328 2013-05-24
2014EP-0175292 2009-07-18
2014US-14320261 2014-06-30
2014US-14558681 2014-12-02
2016US-15172393 2016-06-03
2016US-15369657 2016-12-05
2017US-15643787 2017-07-07

IPC - International classification

A01K-067/027	A61K-031/7088	A61K-038/00
A61K-038/16	A61K-038/17	A61K-038/19
A61K-039/395	A61K-045/00	A61K-047/48
A61K-047/50	A61K-048/00	A61K-049/00
A61K-051/00	A61P-003/00	A61P-019/02
A61P-025/00	A61P-025/28	A61P-029/00
A61P-031/00	A61P-035/00	A61P-037/06
A61P-043/00	C07H-021/04	C07K-001/00
C07K-014/00	C07K-014/525	C07K-014/705
C07K-016/00	C07K-017/00	C07K-019/00
C12N-001/15	C12N-001/19	C12N-001/20
C12N-001/21	C12N-005/00	C12N-005/02
C12N-005/10	C12N-015/00	C12N-015/09
C12N-015/11	C12N-015/18	C12N-015/62*
C12N-015/74	C12N-015/79	C12P-021/06
C12Q-001/68		

CPC - Cooperative classification

A61K-038/00	C07K-014/525*	C07K-014/705/75
C07K-014/705/78	C07K-016/00	C07K-2317/41
C07K-2317/52	C07K-2317/55	C07K-2319/00
C07K-2319/22	C07K-2319/30	C07K-2319/32
C07K-2319/35	C07K-2319/74	C12N-015/62
C12N-015/79		

PCL - US patent classification

PCLO:	530351000*	424085100*	424085100*
530351000*			
PCLX:	424085100*	435069100	435252300
435320100	435325000	435348000	435369000
435471000	530350000	530351000*	530387300
536023400			

Family

CA2910512	A1	2010-01-28	SMT201500135	B	2015-07-09	
WO2010010051	A1	2010-01-28	SI2310509	T1	2015-07-31	
CA2731388	A1	2010-01-28	EP2604693	B1	2016-02-24	
EP2310509	A1	2011-04-20	HUE025236	T2	2016-03-29	
US20110162095	A1	2011-06-30	US9340599	B2	2016-05-17	
JP2011528562	A	2011-11-24	EP2806029	B1	2016-05-25	
US8450460	B2	2013-05-28	ES2571879	T3	2016-05-27	
EP2604693	A2	2013-06-19	DK2604693	T3	2016-05-30	
EP2604693	A3	2014-01-08	US9359420	B2	2016-06-07	

US20140056843	A1	2014-02-27		US20160272695	A1	2016-09-22
EP2806029	A1	2014-11-26		PL2604693	T3	2016-09-30
JP2014230545	A	2014-12-11		JP6046089	B2	2016-12-14
JP2014230546	A	2014-12-11		EP3103875	A1	2016-12-14
US8921519	B2	2014-12-30		CY1116288	T1	2017-02-08
EP2310509	B1	2015-01-21		JP2017029158	A	2017-02-09
JP5674155	B2	2015-02-25		US20170081381	A1	2017-03-23
US20150110734	A1	2015-04-23		JP6140117	B2	2017-05-31
DK2310509	T3	2015-04-27		JP2017128607	A	2017-07-27
US20150125419	A1	2015-05-07		US9725495	B2	2017-08-08
PT2310509	E	2015-05-19		US20170313752	A1	2017-11-02
HRP20150425	T1	2015-06-05		CA2731388	C	2018-05-01
ES2538122	T3	2015-06-17				

(EP3103875)

The present invention refers to single-chain fusion proteins comprising three soluble TNF superfamily (TNFSF) cytokine domains and nucleic acid molecules encoding these fusion proteins.The fusion proteins are substantially non-aggregating and suitable for therapeutic, diagnostic and/or research applications.

Figure 1



Figure 2



Images

Figure 1



Figure 2



Tnf superfamily collectin fusion proteins
EP2484691 A1

Current assignees

APOGENIKUSU
APOGENIX*
APOGENIX*US

Inventors

HILL OLIVER
GIEFFERS CHRISTIAN
THIEMANN MEINOLF
BRANSCHÄDEL MARCUS

Priority data including date

2007EP-0013506 2007-07-10
2008CA-2692802 2008-07-10
2008EP-0773964 2008-07-10
2008WO-EP05644 2008-07-10
2010US-12668188 2010-03-24
2012EP-0166865 2008-07-10
2013US-13776559 2013-02-25
2014US-14322830 2014-07-02
2015US-14968198 2015-12-14
2016EP-0150412 2008-07-10
2016US-15367434 2016-12-02

IPC - International classification

A01K-067/027	A61K-031/7088	A61K-035/12
A61K-038/00	A61K-038/16	A61K-038/19
A61K-045/00	A61K-048/00	A61P-003/00
A61P-019/02	A61P-025/00	A61P-029/00
A61P-031/00	A61P-035/00	A61P-037/02
A61P-037/06	A61P-043/00	C07H-021/02
C07H-021/04	C07K-001/00	C07K-005/083
C07K-007/06	C07K-007/08	C07K-014/00
C07K-014/42	C07K-014/47	C07K-014/52
C07K-014/525*	C07K-014/705*	C07K-014/785
C07K-016/00	C07K-017/00	C07K-019/00
C12N-001/20	C12N-001/21	C12N-005/00
C12N-005/02	C12N-005/10	C12N-015/00
C12N-015/09	C12N-015/28	C12N-015/62
C12N-015/74	C12P-021/06	G01N-033/566

CPC - Cooperative classification

C07K-014/42	C07K-014/47	C07K-014/47/26
C07K-014/525	C07K-014/705/75*	C07K-019/00
C07K-2319/00	C07K-2319/02	C07K-2319/21
C07K-2319/22	C07K-2319/32	C07K-2319/70
C12N-015/62		

PCL - US patent classification

PCLO:	530350000*	530351000*	435348000*
530351000*			
PCLX:	435069100	435252300	435252330
435254200	435320100	435325000	435348000*
435366000	435419000	435471000	530351000*
530399000	536023100	536023400	

Family

CA2963124	A1	2009-01-15	US9212211	B2	2015-12-15
CA2860950	A1	2009-01-15	EP2484691	B1	2016-01-13
WO2009007120	A2	2009-01-15	ES2560871	T3	2016-02-23
CA2692802	A1	2009-01-15	ES2567704	T3	2016-04-26
AU2008274490	A1	2009-01-15	US20160176941	A1	2016-06-23
WO2009007120	A3	2009-03-12	EP3072903	A1	2016-09-28
EP2176288	A2	2010-04-21	JP6002903	B2	2016-10-05
US20100199364	A1	2010-08-05	JP6029646	B2	2016-11-24
JP2010532978	A	2010-10-21	US9527897	B2	2016-12-27
EP2484691	A1	2012-08-08	US20170081386	A1	2017-03-23
US8383774	B2	2013-02-26	CA2692802	C	2017-05-30

US20130178604	A1	2013-07-11	CA2860950	C	2017-08-01
AU2008274490	B2	2014-02-27	EP3072903	B1	2017-10-25
US8907063	B2	2014-12-09	ES2657801	T3	2018-03-06
JP2015057442	A	2015-03-26	EP3321277	A1	2018-05-16
US20150126709	A1	2015-05-07	US10000550	B2	2018-06-19
EP2176288	B1	2015-11-04			

(EP3321277)

The present invention refers to a fusion protein comprising a TNF-superfamily (TNFSF) cytokine or a receptor binding domain thereof fused to a collectin trimerization domain, to a nucleic acid molecule encoding the fusion protein, and to a cell comprising the nucleic acid molecule.The fusion protein is present as a trimeric complex or as an oligomer thereof.The fusion protein, the nucleic acid, and the cell is suitable as pharmaceutical composition or for therapeutic, diagnostic and/or research applications.

Figure 1

SEC of affinity purified CD95L-ASPD



Images

Figure 1

SEC of affinity purified CD95L-ASPD



Single-chain tl1a receptor agonist proteins
WO201772080 A1

Current assignees
APOGENIX*

Inventors
GIEFFERS CHRISTIAN
HILL OLIVER
THIEMANN MEINOLF
SCHNYDER TIM

Priority data including date
2015US-62247671 2015-10-28
2016WO-EP75574 2016-10-24

IPC - International classification

A61K-038/17	C07K-014/705*	C12N-015/62

CPC - Cooperative classification

A61K-038/00	C07K-014/705/75*	C07K-2319/00
C07K-2319/22	C07K-2319/30	C07K-2319/32
C07K-2319/35	C07K-2319/74	

Family

CA3003511	A1	2017-05-04		WO2017072080	A1	2017-05-04	

(WO201772080)
Provided herein are specific TL1A receptor agonist proteins, nucleic acids encoding the same, and methods of treating a subject having a TL1A-associated disease or disorder.The TL1A receptor agonist proteins provided herein comprise three soluble TL1A domains and an Fc fragment.The TL1A receptor agonist proteins are substantially non- aggregating and suitable for therapeutic, diagnostic and/or research applications.



Figure 4

Images



Figure 4

Single-chain cd27-receptor agonist proteins
WO201768192 A1

Current assignees

APOGENIX*

Inventors

GIEFFERS CHRISTIAN
HILL OLIVER
THIEMANN MEINOLF
SCHNYDER TIM

Priority data including date

2015US-62245689 2015-10-23
2016WO-EP75579 2016-10-24

IPC - International classification

A61K-038/17* C07K-014/705* C07K-016/28

CPC - Cooperative classification

A61K-038/00 C07K-014/705/75 C07K-016/28/09*
C07K-016/28/18 C07K-2319/00 C07K-2319/22
C07K-2319/30 C07K-2319/32 C07K-2319/35
C07K-2319/74

Family

CA3002602	A1	2017-04-27		AU2016341409	A1	2018-05-10
WO2017068192	A1	2017-04-27				

(WO201768192)
Provided herein are specific CD27 receptor agonist proteins, nucleic acids encoding the same, and methods of treating a subject having a CD27L-associated disease or disorder.The CD27 receptor agonist proteins provided herein comprise three soluble CD27L domains and an Fc fragment.The CD27 receptor agonist proteins are substantially non-aggregating and suitable for therapeutic, diagnostic and/or research applications.

1 of 10



Figure 1

Images



Figure 1

Single-chain cd137-receptor agonist proteins
WO201768183 A1

Current assignees
APOGENIX*

Inventors
GIEFFERS CHRISTIAN
HILL OLIVER
THIEMANN MEINOLF
SCHNYDER TIM

Priority data including date
2015US-62245838 2015-10-23
2016WO-EP75543 2016-10-24

IPC - International classification
C07K-014/705 C12N-015/62*

CPC - Cooperative classification
C07K-014/705/75* C07K-2319/30 C07K-2319/32
C07K-2319/74

Family

CA3002588	A1	2017-04-27		AU2016341400	A1	2018-05-10	
WO2017068183	A1	2017-04-27					

(WO201768183)
Provided herein are specific CD137 receptor agonist proteins, nucleic acids encoding the same, and methods of treating a subject having a CD137L-associated disease or disorder.The CD137 receptor agonist proteins provided herein comprise three soluble CD137L domains and an Fc fragment.The CD137 receptor agonist proteins are substantially non-aggregating and suitable for therapeutic, diagnostic and/or research applications.



Figure 1

Images





Figure 1

Single-chain ox40-receptor agonist proteins
WO201768181 A1

Current assignees

APOGENIX*

Inventors

GIEFFERS CHRISTIAN
HILL OLIVER
THIEMANN MEINOLF
SCHNYDER TIM

Priority data including date

2015US-62245678 2015-10-23
2016WO-EP75540 2016-10-24

IPC - International classification

C07K-014/705*

CPC - Cooperative classification

C07K-014/705/75* C07K-2319/30

Family

CA3002600 A1 2017-04-27 WO2017068181 A1 2017-04-27

(WO201768181)
Provided herein are specific OX40 receptor agonist proteins, nucleic acids encoding the same, and methods of treating a subject having an OX40L-associated disease or disorder.The OX40 receptor agonist proteins provided herein comprise three soluble OX40L domains and an Fc fragment.The OX40 receptor agonist proteins are substantially non-aggregating and suitable for therapeutic, diagnostic and/or research applications.



Figure 1

Images



Figure 1

Single-chain light receptor agonist proteins
WO201768180 A1

Current assignees

APOGENIX*

Inventors

GIEFFERS CHRISTIAN
HILL OLIVER
THIEMANN MEINOLF
SCHNYDER TIM

Priority data including date

2015US-62245943 2015-10-23
2016WO-EP75536 2016-10-24

IPC - International classification

C07K-014/705* C12N-015/62

CPC - Cooperative classification

C07K-014/52* C07K-2319/02 C07K-2319/30

Family

CA3002587	A1	2017-04-27	AU2016342420	A1	2018-04-26	
WO2017068180	A1	2017-04-27				

(WO201768180)
Provided herein are specific LIGHT receptor agonist proteins, nucleic acids encoding the same, and methods of treating a subject having a LIGHT-associated disease or disorder.The LIGHT receptor agonist proteins provided herein comprise three soluble LIGHT domains and an Fc fragment.The LIGHT receptor agonist proteins are substantially non-aggregating and suitable for therapeutic, diagnostic and/or research applications.



Figure 1

Images



Figure 1

Single-chain gitr-receptor agonist proteins
WO201768185 A1

Current assignees

APOGENIX*

Inventors

GIEFFERS CHRISTIAN
HILL OLIVER
THIEMANN MEINOLF
SCHNYDER TIM

Priority data including date

2015US-62245815 2015-10-23
2016WO-EP75552 2016-10-24

IPC - International classification

A61K-038/17	C07K-014/705*	C12N-015/62

CPC - Cooperative classification

A61K-038/00	C07K-014/705/75*	C07K-2319/00
C07K-2319/22	C07K-2319/30	C07K-2319/32
C07K-2319/35	C07K-2319/74	

Family

CA3002741	A1	2017-04-27	AU2016341402	A1	2018-05-10	
WO2017068185	A1	2017-04-27				

(WO201768185)

Provided herein are specific GITR receptor agonist proteins, nucleic acids encoding the same, and methods of treating a subject having a GITRL-associated disease or disorder.The GITR receptor agonist proteins provided herein comprise three soluble GITRL domains and an Fc fragment.The GITR receptor agonist proteins are substantially non-aggregating and suitable for therapeutic, diagnostic and/or research applications.



Figure 4

Images



Figure 4

Anti-cd95l antibody
WO201751002 A1

Current assignees

APOGENIX*

Inventors

GIEFFERS Christian
HILL Oliver
THIEMANN Meinolf
SYKORA Jaromir
MERZ Christian
SCHNYDER Tim
FRICKE Harald

Priority data including date

2015EP-0186468 2015-09-23
2016WO-EP72757 2016-09-23

IPC - International classification

C07K-016/28*

CPC - Cooperative classification

C07K-016/28/75*	C07K-2317/21	C07K-2317/24
C07K-2317/34	C07K-2317/55	C07K-2317/565
C07K-2317/622	C07K-2317/76	C07K-2317/92

Family

CA2999116	A1	2017-03-30		CN108290950	A	2018-07-17	
WO2017051002	A1	2017-03-30		US20180208664	A1	2018-07-26	
AU2016325482	A1	2018-04-12					

(US20180208664)

The present invention relates to a specific CD95L antibody and to the use thereof in the treatment or diagnosis of diseases involving CD95L-induced signalling, e.g. cancer diseases.



Images

A

Peptide array with anti-CD95L clone 119-4



B

Intensity plot derived from peptide array of clone 119-4



Consensus epitope of clone 119-4 :RNSKYPQD

Method of predicting the responsiveness of a cancer disease to treatment
WO201709429 A1

Current assignees

APOGENIX*

Inventors

MERZ CHRISTIAN

GIEFFERS CHRISTIAN

Priority data including date

2015EP-0176702 2015-07-14

IPC - International classification

C07K-014/705 C07K-016/28 C12Q-001/68*

CPC - Cooperative classification

C07K-014/47/03 C07K-014/705/75 C12Q-001/68/86*

C12Q-2600/106 C12Q-2600/154 C12Q-2600/158

Family

WO2017009429 A1 2017-01-19

(WO201709429)

The present invention relates to a method of predicting or/and determining the responsiveness of a cancer disease to treatment with an inhibitor of CD95/CD95L signaling comprising the steps of (i) determining the methylation level of an CpG site in a DNA sequence located upstream the CD95L gene in a sample obtained from a patient; or/and (ii) determining the presence of an SNP in a DNA sequence located upstream the CD95L gene in a sample obtained from a patient; and (iii) predicting or/and determining the responsiveness of the cancer disease according to said methylation level.



Figure 1: CpG-dinucleotides in the putative FASLG gene promotor region

Homo sapiens Fas ligand (TNF superfamily, member 6) (FASLG)
RefSeqGene (LRG_58) on chromosome 1 (NC_000011.1)
NCBI Reference Sequence: NG_007269.1
hown are 1 kb upstream of gene/mRNA start, 5'-UTR and exon 1 of the FASLG gene (CpG2 and CpG5 boxes indicated)

CpG5

CpG2

```
3961 ggtcagttgg gctcagtgca gtggctcatg cctgtaattc cagcactttg ggaaactgag gcaggaggat gtcttgaagc
4041 taggagtttg agacaagcct gggcaacata gcaagtcccc atctgtacaa aaaaaaaaaa gaataaatta gtcaggtgta
4121 gtgacttatg cctataatcc cagctactca ggaggccaag gcaagaggat tgcttgagcc caggagtttg aggctgcagt
4201 taactacgat agcaccactg cactccagcc tgggtgacag agtgagactc tgtctctatt taaataaata agtaaataaa
4281 taaactgggc aaacaatgaa aatgaaaaca ttgcgaaata caaagcagct ctgtgggttc cactggtttg cagcctctga
4361 tctaatttct aaagtgggtg tagcaggttt ttaacctgta aattatggtg atcggcaggt cagggtaaat ggtagttgtg
4441 tgtggggaag agatgatggc aacagatgtt ttcctcctgc aaaaactaaa atgtgggagt gacttctctg gccatgactc
4521 catggtctct cccctcagag ccattttcag taaaattttt atagtttaaa aaatacggtt ctgaacaatt tttgttagag
4601 ttattttggg atttttaaat agtttttgg ttgtgtatat ggtagaattc ttaaaattat acaattataa tgtataaaaa
4681 agcatgcaat tataattcat aaaattatag ccccactgac cattctcctg tagctgggag cagttcacac taacagggct
4761 ataccccccat gctgacctgc tctgcaggat cccaggaagg tgagcatagc ctactaacct gtttgggtag cacagcgaca
4841 gcaactgagg ccttgaaggc tgttatcaga aaattgtggg cggaaacttc caggggtttg ctctgagctt cttgaggctt
4921 ctcagcttca gctgcaaagt gagtgggtgt ttctttgaga agcagaatca gagagagaga gatagagaaa gagaaagaca
5001 gaggtgtttc ccttagctat ggaaactcta taagagagat ccagcttgcc tcctcttgag cagtcagcaa cagggtcccg
5081 tccttgacac ctcagcctct acaggactga gaagaagtaa aaccgtttgc tggggctggc ctgactcacc agctgccatg
5161 cagcagccct tcaattaccc atatccccag atctactggg tggacagcag tgccagctct ccctgggccc ctccaggcac
5241 agttcttccc tgtccaacct ctgtgcccag aaggcctggt caaaggaggc caccaccacc accgccaccg ccaccactac
5321 cacctccgcc gccgccgcca ccactgcctc cactaccgct gccacccctg aagaagagag ggaaccacag cacaggcctg
5401 tgtctccttg tgatgttttt catggttctg gttgccttgg taggattggg cctggggatg tttcagctct tccacctaca
5481 gaaggagctg gcagaactcc gagaggtaag cctgccggca
```

- only 6 CpG sites found within 1 kb upstream of FASLG gene start (vs. 63 if statistically distributed)
- CpG2 methylation status (red box) correlates with patient response to APG101 therapy
- CpG5 (blue box) represents germline sequence of FASL -844C/T variation rs763110

Fusion proteins forming trimers
JP2016210791 A

Current assignees
APOGENIX*

Inventors
OLIVER HILL
MARCUS BRANSCHAEDEL
CHRISTIAN GIEFFERS
MEINOLF THIEMANN

Priority data including date
2016JP-0152656 2016-08-03

IPC - International classification

A61K-038/00	A61K-039/395	A61P-003/00
A61P-025/28	A61P-029/00	A61P-031/00
A61P-035/00	A61P-037/06	A61P-043/00
C07K-014/52	C07K-014/715	C07K-016/46
C07K-019/00*		

Family

JP2016210791	A	2016-12-15	

(JP2016210791)
PROBLEM TO BE SOLVED: To provide fusion proteins that form trimers, which proteins enable efficient production of recombinants provided with both good trimerization properties and improved pharmaceutical properties.SOLUTION: The invention provides a fusion protein comprising: (i) collectin family trimer-forming domain comprising a. a collectin family carbohydrate recognition domain and b. a collectin family neck region; (ii) a linker element; and (iii) an effector polypeptide, where the effector polypeptide is located at the N-terminus of the collectin family neck region.As described herein, the fusion proteins and nucleic acids encoding the same are suitable as pharmaceutical compositions or for therapeutic, diagnostic and/or research applications.SELECTED DRAWING: None

Figure 1



Images

Figure 1

親和性精製されたCD95L－ASPDのSEC



Proteã**nas agonistas de receptor de cd40 de cadeia simples
BR112017023646 A1

Current assignees

APOGENICUS

APOGENIX*

Inventors

SCHNYDER OLIVER HILL CHRISTIAN GIEFFERS MEINOLF THIEMANN TIM

Priority data including date

2015US-62156813 2015-05-04

2016WO-EP59983 2016-05-04

IPC - International classification

A61K-038/00	A61K-038/16	A61P-003/00
A61P-019/02	A61P-025/00	A61P-029/00
A61P-031/00	A61P-035/00	A61P-037/06
A61P-043/00	C07K-014/525	C07K-014/705*
C07K-016/00	C07K-019/00	C12N-001/15
C12N-001/19	C12N-001/21	C12N-005/10
C12N-015/09	G01N-033/68	

CPC - Cooperative classification

A61K-038/00	C07K-014/705/75*	C07K-2319/02
C07K-2319/22	C07K-2319/30	C07K-2319/32
C07K-2319/35	C07K-2319/74	G01N-033/68
G01N-2333/70575		

Family

CA2984350	A1	2016-11-10	CN107709355	A	2018-02-16
WO2016177771	A1	2016-11-10	EP3292143	A1	2018-03-14
WO2016177771	A9	2017-06-29	MX2017014140	A	2018-03-15
IN201737038386	A	2017-11-17	BR112017023646	A1	2018-04-03
AU2016257000	A1	2017-11-23	JP2018515072	A	2018-06-14
KR20170138585	A	2017-12-15	BR112017023646	A2	2018-07-17

(EP3292143)

Provided herein are specific CD40 receptor agonist proteins, nucleic acids encoding the same, and methods of treating a subject having a CD40L-associated disease or disorder.The CD40 receptor agonist proteins provided herein comprise three soluble CD40L domains and an Fc fragment.The CD40 receptor agonist proteins are substantially non-aggregating and suitable for therapeutic, diagnostic and/or research applications.



Figure 1

Images



Figure 1

Device for adjusting the seat inclination of a motor vehicle seat
EP3010753 A1

Current assignees

APOGENIX

JOHNSON CONTROLS COMPONENTS*

Inventors

ENNS VIKTOR

DILL THOMAS

WIEGE JAKOB

Priority data including date

2013DE-10106410 2013-06-19

2014WO-EP62824 2014-06-18

IPC - International classification

A47C-007/02	A47C-007/14	B60N-002/02
B60N-002/10	B60N-002/18	B60N-002/62
B60N-002/68*		

CPC - Cooperative classification

B60N-002/10*	B60N-002/18/39	B60N-002/62
B60N-002/68	B60N-002/68/2	B60N-002/68/6

PCL - US patent classification

PCLO: 297313000*

Family

WO2014202667	A1	2014-12-24	CN105392669	A	2016-03-09
DE102013106410	A1	2014-12-24	EP3010753	A1	2016-04-27
DE102013106410	B4	2015-02-12	US20160144747	A1	2016-05-26
IN10522/DELNP/2015	A	2016-02-12	JP2016523196	A	2016-08-08
KR20160020536	A	2016-02-23	CN105392669	B	2017-11-21

(EP3010753)

The invention relates to a device for adjusting the seat inclination of a motor vehicle seat, comprising a seat frame and a seat shell, which are connected to each other in an articulated manner by means of two fastening elements, which each extend through a respective accommodating opening on the seat frame and a respective bearing opening on the seat shell.According to the invention, in order to provide a device for adjusting the seat inclination for a motor vehicle seat that can be produced simply and installed fully automatically, has a lower total weight, and has especially high stability, the material of the seat shell has a greater material thickness in the region of the bearing openings than in the other regions of the seat shell.



Images



Método de diagnóstico de câncer
BR112015027249 A1

Current assignees

APO TRANSGENIC SCAN

APOGENIX*

Inventors

CHRISTIAN GIEFFERS

HARALD FRICKE

JAROMIR SYKORA

Priority data including date

2013EP-0165784 2013-04-29

2014EP-0720964 2014-04-29

2014WO-EP58746 2014-04-29

IPC - International classification

A61K-039/395 A61K-045/00 A61P-035/00

A61P-035/04 C07K-014/705 C12Q-001/02

G01N-033/574*

CPC - Cooperative classification

A61K-038/00 C07K-014/705/78 C07K-2319/30

G01N-033/574/07 G01N-033/574/92* G01N-2333/70575

G01N-2333/70578 G01N-2800/52

PCL - US patent classification

PCLO: 424134100*

PCLX: 435007230 436501000

Family

CA2910332	A1	2014-11-06		US20160103132	A1	2016-04-14
WO2014177576	A1	2014-11-06		MX2015015015	A	2016-07-21
AU2014261505	A1	2015-11-12		JP2016524694	A	2016-08-18
BR112015027249	A1	2015-12-08		BR112015027249	A2	2017-09-26
CN105393121	A	2016-03-09		EP2992330	B1	2018-04-18
EP2992330	A1	2016-03-09		CN105393121	B	2018-04-24

(BR112015027249)

resumo patente de invenção: "método de diagnóstico de câncer". a presente invenção refere-se a um método para o diagnóstico de uma doença cancerosa, compreendendo (a) determinação da expressão de cd95l em uma amostra de câncer e (b) classificação da doença de câncer de acordo com o nível de expressão de cd95l.

Figure 1



Images

Figure 1



Combination of cd95/cd95l inhibition and cancer immunotherapy
EP3161003 A2

Current assignees

APOGENIX*

Inventors

KUNZ CLAUDIA
FRICKE HARALD
HÖGER THOMAS
GAMER JUERGEN
WICK WOLFGANG

Priority data including date

2014EP-0174757 2014-06-27
2015WO-EP64762 2015-06-29

IPC - International classification

A61K-038/17	A61K-039/395	A61P-035/00
C07K-014/705	C07K-016/28*	C07K-016/30
G01N-033/574		

CPC - Cooperative classification

A61K-038/17/7*	A61K-039/395/58	A61K-2039/505
C07K-014/705/75	C07K-016/28/18	C07K-016/30/15
C07K-016/30/23	C07K-016/30/46	C07K-016/30/53
C07K-016/30/69	C07K-2317/31	C07K-2317/76
C07K-2319/30	G01N-033/574/92	G01N-2333/70596

Family

WO2015197874	A2	2015-12-30		US20170106048	A1	2017-04-20	
WO2015197874	A3	2016-03-17		EP3161003	A2	2017-05-03	

(EP3161003)

The present invention relates to the treatment of cancer using a combination of an inhibitor of the CD95/CD95L signaling system and an immunotherapeutic agent, e.g. a cancer vaccine or a checkpoint inhibitor.Another aspect of the invention is the prognosis of responsiveness of a cancer to the treatment with a combination of a CD95 inhibitor and an immunotherapeutic agent.Further disclosed are preparations and kits for use in these methods.

Figure 1



Images

Figure 1



Diagnostic anti-cd95l antibody
EP3137909 A1

Current assignees

APOGENIX*

Inventors

FRICKE HARALD

GIEFFERS CHRISTIAN

SYKORA JAROMIR

Priority data including date

2014WO-EP58746 2014-04-29

2015WO-EP59354 2015-04-29

IPC - International classification

C07K-016/28 G01N-033/574*

CPC - Cooperative classification

A61K-2039/505	C07K-016/28/75*	C07K-2317/32
C07K-2317/565	G01N-033/574/84	G01N-033/574/92
G01N-2333/70575	G01N-2800/52	G01N-2800/54

Family

WO2015165973	A1	2015-11-05	EP3137909	A1	2017-03-08	
US20170044264	A1	2017-02-16	EP3137909	B1	2018-06-06	

(EP3137909)

The present invention relates to a specific CD95L antibody and to the use thereof in the diagnosis of a cancer disease.

Figure 1



Images

Figure 1



Proteínas do agonista do receptor trail de cadeia única
BR112016024515 A1

Current assignees

ABBVIE
APOGENICUS
APOGENIX
AVVI

Inventors

CHRISTIAN GIEFFERS
DARREN C PHILLIPS
FRITZ G BUCHANAN
MEINOLF THIEMANN
OLIVER HILL
SUSAN E LAPPE

Priority data including date

2014US-61983152 2014-04-23
2015EP-0721089 2015-04-23
2015US-14694358 2015-04-23
2015WO-US27270 2015-04-23

IPC - International classification

A61K-038/00*	A61K-038/17	A61K-038/19
A61K-039/395	A61K-047/68	A61P-003/00
A61P-019/02	A61P-025/00	A61P-025/28
A61P-029/00	A61P-031/00	A61P-035/00
A61P-037/00	A61P-037/02	A61P-037/06
A61P-043/00	C07K-014/00	C07K-014/47
C07K-014/52	C07K-014/525	C07K-014/705*
C07K-016/00	C07K-016/28	C07K-016/30
C07K-019/00	C12N-005/10	C12N-015/09
C12N-015/13	C12N-015/62	C12N-015/85

CPC - Cooperative classification

A61K-038/00	A61K-038/17/7	C07K-014/705/75*
C07K-2319/00	C07K-2319/30	

PCL - US patent classification

PCLO: 424134100*
PCLX: 435320100 435328000 530387300 536023400

Family

CA2946402	A1	2015-10-29		VN51349	A	2017-03-27
WO2015164588	A1	2015-10-29		PE02992017	A1	2017-05-06
UY36095	A	2015-10-30		CR20160516	A	2017-05-10
US20150337027	A1	2015-11-26		JP2017513503	A	2017-06-01
TW201620928	A	2016-06-16		CL2016002683	A1	2017-07-07
AR100168	A1	2016-09-14		MX2016013858	A	2017-08-02
BR112016024515	A1	2016-11-01		BR112016024515	A2	2017-10-10
AU2015249649	A1	2016-11-10		US9908927	B2	2018-03-06
SG11201608767X	A	2016-11-29		EP3134430	B1	2018-03-21
PH12016502079	A1	2016-12-19		PT3134430	T	2018-04-20
KR20170012257	A	2017-02-02		LT3134430	T	2018-05-10
IN201617038061	A	2017-02-10		DK3134430	T3	2018-05-22
DOP2016000284	A	2017-02-15		RU2016145608	A	2018-05-28
CN106459221	A	2017-02-22		SI3134430	T1	2018-05-31
EP3134430	A1	2017-03-01		ES2672368	T3	2018-06-14

(BR112016024515)
resumo ?proteínas do agonista do receptor trail de cadeia única? proteínas do agonista do receptor trail específicas, ácidos nucleicos que codificam as mesmas e métodos para tratar um sujeito que apresenta uma doença ou transtorno associada a trail são fornecidos neste relatório. as proteínas



do agonista do receptor trail fornecidas neste relatório compreendem três domínios trail solúveis e um fragmento fc. as proteínas do agonista do receptor trail são substancialmente não agregadoras e adequadas para aplicações terapêuticas, de diagnóstico e/ou de pesquisa.

Images


COOH
COOH
C_H3
C_H3
IgG1-Fc
N-Glycosylations
C_H2
C_H2
Hinge + Linker
NH_2
NH_2
scTRAIL-RBD
• scTRAIL-RBD = single chain TRAIL receptor binding domain
• Linker = Gly-Ser linker
• IgG-Fc = human IgG1 derived Fc [Hinge-CH2-CH3]

Fusion proteins forming trimers
JP2015143270 A

Current assignees

APOGENIX*

Inventors

OLIVER HILL
MARCUS BRANSCHAEDEL
CHRISTIAN GIEFFERS
MEINOLF THIEMANN

Priority data including date

2015JP-0090114 2015-04-27

IPC - International classification

A61K-038/00	A61K-039/395	A61P-003/00
A61P-025/28	A61P-029/00	A61P-031/00
A61P-035/00	A61P-037/06	A61P-043/00
C07K-014/47	C07K-016/24	C07K-016/28
C07K-019/00*	C12N-015/09	

Family

JP2015143270 A 2015-08-06

(JP2015143270)
PROBLEM TO BE SOLVED: To provide fusion proteins forming trimers which allow efficient recombinant manufacture combined with good trimerization properties and improved pharmaceutical properties.SOLUTION: The present invention relates to a fusion protein comprising (i) a collectin family trimerization domain comprising a. a collectin family Carbohydrate Recognition Domain; and b. a collectin family neck region; (ii) a linker element; and(iii) an effector polypeptide, wherein the effector polypeptide is located N-terminally in the collectin family neck region.The fusion proteins, and the nucleic acid encoding the same are suitable as pharmaceutical composition or for therapeutic, diagnostic and/or research applications as described herein.

Figure 1



Images

Figure 1

親和性精製されたCD95L－ASPDのSEC



Method of predicting the responsiveness of a cancer disease to treatment on the basis of dna methylation
EP3094744 A1

Current assignees
APOGENIX*

Inventors
FRICKE HARALD
WICK WOLFGANG
WIESTLER BENEDIKT

Priority data including date
2014EP-0151345 2014-01-15
2015EP-0700459 2015-01-15
2015WO-EP50648 2015-01-15

IPC - International classification
C12Q-001/68*

CPC - Cooperative classification
C12Q-001/68/86* C12Q-2600/106 C12Q-2600/154

Family
WO2015107105 A1 2015-07-23 EP3094744 A1 2016-11-23

(EP3094744)
The present invention relates to a method of predicting/determining the responsiveness of a cancer disease to treatment with an inhibitor of CD95/CD95L signalling comprising the steps of i) determining the methylation level of a DNA sequence located upstream of and/or in a gene involved in CD95/CD95L signalling in a sample obtained from a patient; and ii) predicting/determining the responsiveness of the cancer disease according to said methylation level.

Figure 1



Images

Figure 1



Fusion proteins forming trimers
JP2014218510 A

Current assignees

APOGENIX*

Inventors

OLIVER HILL
MARCUS BRANSCHAEDEL
CHRISTIAN GIEFFERS
MEINOLF THIEMANN

Priority data including date

2014JP-0163362 2014-08-11

IPC - International classification

A61K-038/00	A61K-039/395	A61P-003/00
A61P-017/00	A61P-019/00	A61P-025/28
A61P-029/00	A61P-031/00	A61P-035/00
A61P-037/06	A61P-043/00	C07K-014/47
C07K-016/24	C07K-016/28	C07K-019/00*
C12N-015/09		

Family

JP2014218510 A 2014-11-20

(JP2014218510)
PROBLEM TO BE SOLVED: To provide fusion proteins forming trimers which allow efficient recombinant manufacture combined with good trimerization properties and improved pharmaceutical properties.SOLUTION: The present invention relates to a fusion protein comprising (i) a collectin family trimerization domain comprising a. a collectin family Carbohydrate Recognition Domain; and b. a collectin family neck region; (ii) a linker element; and(iii) an effector polypeptide, wherein the effector polypeptide is located N-terminally in the collectin family neck region.The fusion proteins, and the nucleic acid encoding the same are suitable as pharmaceutical composition or for therapeutic, diagnostic and/or research applications as described herein.

Figure 1

親和性精製されたCD95L－ASPDのSEC



Images

Figure 1

親和性精製されたCD95L－ASPDのSEC



Composição compreendendo uma mistura de isoformas de cd95-fc
BR112015000732 A1

Current assignees

APODZHINIKS

APOGENICS APOGENIX*

APOGENIX*

Inventors

HILL OLIVER

GIEFFERS CHRISTIAN

THIEMANN MEINOLF

Priority data including date

2012EP-0176978 2012-07-18
2012EP-0176980 2012-07-18
2013EP-0737631 2013-07-18
2013EP-0742412 2013-07-18
2013WO-EP65248 2013-07-18
2013WO-EP65250 2013-07-18
2015US-14415866 2015-03-20
2015US-14415871 2015-01-20
2016US-15131219 2016-04-18
2016US-15239127 2016-08-17
2018US-15902175 2018-02-22

IPC - International classification

A61K-038/17	A61K-039/00	A61K-039/395
A61P-035/00	C07K	C07K-001/16
C07K-007/08	C07K-014/525	C07K-014/705*
C07K-016/00	C07K-016/18	C07K-019/00
C12N	C12N-001/15	C12N-001/19
C12N-001/21	C12N-005/10	C12N-015/09
C12N-015/62	C12P-021/02	

CPC - Cooperative classification

A61K-038/17/93*	A61K-039/395/5	C07K-007/08*
C07K-014/00	C07K-014/435	C07K-014/525
C07K-014/705	C07K-014/705/78*	C07K-016/00
C07K-016/18	C07K-019/00	C07K-2316/52
C07K-2317/52	C07K-2317/524	C07K-2317/526
C07K-2319/00	C07K-2319/02	C07K-2319/30
C07K-2319/74	C12N-015/62	

PCL - US patent classification

PCLO:	424134100*	424085100*	
PCLX:	435069600	435328000	530326000
530351000	530387300	536023100	536023400

Family

CA2878992	A1	2014-01-23	US9315570	B2	2016-04-19	
CA2877989	A1	2014-01-23	US20160235815	A1	2016-08-18	
WO2014013039	A1	2014-01-23	US9434783	B2	2016-09-06	
WO2014013037	A1	2014-01-23	RU2015105330	A	2016-09-10	
AU2013291984	A1	2015-02-05	RU2015105328	A	2016-09-10	
AU2013291982	A1	2015-02-05	US20160362471	A1	2016-12-15	
IL236659	B	2015-02-26	AU2013291982	B2	2017-01-12	
SG11201500134Q	A	2015-03-30	IL236659	B	2017-02-28	
BR112015000732	A1	2015-03-31	US9657083	B2	2017-05-23	
BR112015000641	A1	2015-03-31	BR112015000732	A2	2017-08-15	
KR20150048120	A	2015-05-06	BR112015000641	A2	2017-08-15	
CN104640876	A	2015-05-20	JP6231562	B2	2017-11-15	
CN104662039	A	2015-05-27	AU2013291984	B2	2018-01-18	
EP2875045	A1	2015-05-27	US9908928	B2	2018-03-06	
EP2875044	A1	2015-05-27	RU2648146	C2	2018-03-22	
US20150166633	A1	2015-06-18	RU2648157	C2	2018-03-22	
US20150225475	A1	2015-08-13	NZ703546	A	2018-03-23	
JP2015524403	A	2015-08-24	EP2875045	B1	2018-03-28	
MX2015000731	A	2015-09-04	EP2875044	B1	2018-04-11	
JP2015528006	A	2015-09-24	JP6317739	B2	2018-04-25	

IN0084/KOLNP/2015	A	2015-12-11	UA116889	C2	2018-05-25	
HK1207096	A1	2016-01-22	DK2875045	T3	2018-07-02	
HK1207095	A1	2016-01-22	US20180186856	A1	2018-07-05	

(EP2875044)

The present invention relates to an isolated fusion protein comprising an extracellular CD95 domain or a functional fragment thereof and an Fc domain or functional fragment thereof, formulations providing such fusion protein in a stable form as well as a method for producing such a fusion protein.

Figure 1



Images

Figure 1



Inibidores da via de sinalização cd95 para tratamento de mds e seus usos
BR112015000998 A1

Current assignees

ABERGINI COASE

APODZHINIKS

APOGENICUS

APOGENIX*

Inventors

FRICKE HARALD

FONTENAY MICHAELA

KUNZ CLAUDIA

Priority data including date

2012EP-0176974 2012-07-18

2013EP-0739979 2013-07-18

2013WO-EP65245 2013-07-18

2015US-14415851 2015-01-20

2016US-15392733 2016-12-28

IPC - International classification

A61K	A61K-038/00	A61K-038/17
A61K-038/18	A61K-039/00	A61K-039/395*
A61K-045/06	A61P-007/00	A61P-007/06
A61P-035/00	C07K	C07K-014/00
C07K-014/705	C07K-016/00	C07K-016/28
G01N	G01N-033/569	G01N-033/68

CPC - Cooperative classification

A61K-038/17	A61K-038/17/7	A61K-039/395
A61K-039/395/5	A61K-045/06	C07K-014/705/75
C07K-014/705/78	C07K-016/28/75*	C07K-016/28/78
C07K-2319/30	C07K-2319/32	G01N-033/569
G01N-033/68/63	G01N-2333/70575	G01N-2800/22

PCL - US patent classification

PCLO: 424134100*

PCLX: 530387300

Family

CA2876787	A1	2014-01-23		CN104640568	B	2016-10-19
WO2014013036	A1	2014-01-23		DK2874659	T3	2016-10-24
AU2013291981	A1	2015-01-22		ES2589134	T3	2016-11-10
IL236657	B	2015-02-26		SI2874659	T1	2016-11-30
BR112015000998	A1	2015-03-31		HRP20161164	T1	2016-12-16
KR20150047489	A	2015-05-04		US9540431	B2	2017-01-10
CN104640568	A	2015-05-20		PL2874659	T3	2017-01-31
EP2874659	A1	2015-05-27		HUE029571	T2	2017-03-28
US20150166632	A1	2015-06-18		EP3150224	A1	2017-04-05
MX2015000732	A	2015-08-06		AU2013291981	B2	2017-05-04
JP2015528005	A	2015-09-24		CY1117977	T1	2017-05-17
IN0071/KOLNP/2015	A	2015-12-11		US20170166648	A1	2017-06-15
HK1207003	A1	2016-01-22		BR112015000998	A2	2017-08-15
EP2874659	B1	2016-07-13		UA116104	C2	2018-02-12
RU2015105329	A	2016-09-10		JP6297552	B2	2018-03-20
LT2874659	T	2016-09-12		RU2652348	C2	2018-04-25
PT2874659	T	2016-09-19				

(EP2874659)

The present invention relates to inhibitors of the CD95 signaling pathway for the use in the treatment of Myelodysplastic Syndrom (MDS) wherein the MDS is selected from the IPSS low risk MDS subgroup and/or the IPSS intermediate-1 (int-1) risk MDS subgroup as well as a



method for the diagnosis of MDS.

Images



Figure 1

TNF superfamily collectin fusion proteins
AU2013203061 A1

Current assignees

APOGENIX*

Inventors

HILL OLIVER
GIFFERS CHRISTOPHER
THIEMANN MEINOLF
BRANSCHADEL MARCUS

Priority data including date

2008AU-0274490 2008-07-10
2013AU-0203061 2013-04-09
2014AU-0202645 2014-05-15
2017AU-0201232 2017-02-23

IPC - International classification

A61K-038/19 C07K-014/525* C12N-005/10
C12N-015/28 C12N-015/62

Family

AU2013203061	A1	2013-05-02		AU2017201232	A1	2017-03-16
AU2014202645	A1	2014-06-05		AU2017201232	B2	2018-03-22
AU2013203061	B2	2016-07-28				

(AU2013203061)
Abstract The present invention refers to a fusion protein comprising a TNF-superfamily (TNFSF) cytokine or a receptor binding domain thereof fused to a collectin trimerization domain, to a 5 nucleic acid molecule encoding the fusion protein, and to a cell comprising the nucleic acid molecule.The fusion protein is present as a trimeric complex or as an oligomer thereof.The fusion protein, the nucleic acid, and the cell is suitable as pharmaceutical composition or for therapeutic, diagnostic and/or research applications.

09 Apr 201
2013203061

Figure 1

SEC of affinity purified CD95L-ASPD



Images

Figure 1

SEC of affinity purified CD95L-ASPD



Il-4 receptor and il-13 as prognostic markers for colon and pancreas tumors
US20100111969 A1

Current assignees

APOGENIX*

Inventors

FRICKE HARALD

KORNMANN MARKO

Priority data including date

2008US-61110044 2008-10-31

2009US-12609309 2009-10-30

IPC - International classification

A61K-039/395 C07K-016/24* G01N-033/53

CPC - Cooperative classification

C07K-016/24/4* C07K-2317/73 G01N-033/574/19

G01N-033/574/38 G01N-2333/54

PCL - US patent classification

PCLO: 424158100*

PCLX: 435007920 530387100

Family

US20100111969 A1 2010-05-06

(US20100111969)

The present invention relates to the use of IL-4 receptor and IL-13 expression as diagnostic and/or prognostic markers for tumors, such as colon and pancreas tumors.



Images


A
Cell number (% of untreated control)
240
220
200
180
160
140
120
100
0
1
2
3
4
Time (days)
B
Growth (% of untreated control)
150
125
100
C
Relative difference in cell cycle (% of untreated control)
150
100
50
0
G0/G1 S G2 G0/G1 S G2 G0/G1 S G2
ASPC-1 CAPAN-1 COLO-357

Multimeric TNF receptors
EP2310409 A2

Current assignees

APOGENIX*

Inventors

HILL OLIVER

GIEFFERS CHRISTIAN

FISCHER CARMEN

Priority data including date

2008EP-0010978 2008-06-17

2009EP-0779764 2009-06-15

2009WO-EP57396 2009-06-15

2012EP-0176681 2009-06-15

IPC - International classification

C07H-021/00	C07K-001/00	C07K-014/00
C07K-014/705*	C07K-017/00	C12N-001/20
C12N-005/00	C12N-005/02	C12N-015/00
C12N-015/62	C12N-015/74	C12P-021/06

CPC - Cooperative classification

A61K-038/00	C07K-014/705/78*	C12N-015/62

PCL - US patent classification

PCLO:	530350000*		
PCLX:	435069100	435252300	435320100
435325000	435471000	536023500	

Family

WO2010003766	A2	2010-01-14	EP2540740	A3	2013-04-24
WO2010003766	A3	2010-04-22	US8592557	B2	2013-11-26
EP2310409	A2	2011-04-20	EP2540740	B1	2014-09-10
US20110111494	A1	2011-05-12	ES2524553	T3	2014-12-10
EP2540740	A2	2013-01-02			

(EP2540740)

The present invention refers to fusion proteins comprising a TNF receptor family extracellular domain fused to a trimerization domain, and a nucleic acid molecule encoding the fusion protein.The fusion protein may be present as a trimeric complex.It is suitable for therapeutic, diagnostic and/or research applications.

Figure 1



Figure 2

Images

Figure 1



Figure 2

Binding agents directed against il-4 receptor for the treatment of tumors, inflammatory and immunological disorders
EP2271674 A2

Current assignees

APOGENICUS GESELLSCHAFT MITT BESHRENCKTEL HUFTUNG GERMANY FEDERAL REPUBLIC HEIDELBERG IM NEUENHEIMER FELT 5 8 4 APOGENIX*

Inventors

HILL OLIVER
BRANSCHAEDEL MARCUS
GIEFFERS CHRISTIAN
THIEMANN MEINOLF
MERZ CHRISTIAN

Priority data including date

2008EP-0006750 2008-04-02
2009EP-0726527 2009-03-30
2009WO-EP53756 2009-03-30

IPC - International classification

A61K-031/337	A61K-033/24	A61K-039/395*
A61K-045/00	A61P-011/00	A61P-011/06
A61P-017/00	A61P-017/02	A61P-019/02
A61P-029/00	A61P-031/06	A61P-035/00
A61P-037/00	A61P-043/00	C07H-017/04
C07K-016/28*	C07K-016/30	C07K-016/46

CPC - Cooperative classification

A61K-045/06	A61K-2039/505	C07K-016/24/7
C07K-016/28/66*	C07K-2317/24	C07K-2317/31
C07K-2317/34		

PCL - US patent classification

PCLO:	424131100*		
PCLX:	424133100	424135100	424136100
424139100	424143100	424172100	530387200
530387300	530388220	530389100	

Family

WO2009121847	A2	2009-10-08	EP2271674	A2	2011-01-12	
AU2009231482	A1	2009-10-08	US20110008326	A1	2011-01-13	
WO2009121847	A3	2009-12-03	JP2011518128	A	2011-06-23	

(EP2271674)

The present invention relates to the use of an antigen-binding agent directed against human interleukin-4 receptor for the prevention and/or treatment of tumors, inflammatory and immunological disorders.Further the invention relates to methods of inhibiting the bioactivity of IL-4 without inhibiting binding of IL-4 to IL-4R and particularly to methods for treatment and/or prevention of tumors, inflammatory and immunological disorders, the methods comprising administering to an individual in need thereof an antigen-binding agent with binding affinity for IL-4R.

Figure 1

Variable light chain, humanised (SEQ ID NO: 13)

DIQMTQSPSS LSASVGDRVT ITCSASQDIN NYLNWYQQKPGKAPKLLIYY
TSSLHSGVPS RFSGSGSGTD FTLTISSLQP EDFATYYCQQ
FSNLPWTFGGGTKLEIK

Variable heavy chain, humanised (SEQ ID NO: 14)

EVQLVESGGG LVKPGGSLRL SCAASGFTFN TNAMNWVRQAPGKGLEWVAR
IRSKSNNYAT YYADSVKDRF TLSRDDSKNT LYLQMNSLKT
EDTAVYYCTRDRGWGAMDYW GQGTTVTVSS

Variable heavy chain, humanised (SEQ ID NO: 15)

EVQLVESGGG LVKPGGSLRL SCAASGFTFN TNAMNWVRQAPGKGLEWVAR
IRSKSNNYAT YYADSVKDRF TISRDDSKNT LYLQMNSLKT
EDTAVYYCTRDRGWGAMDYW GQGTTVTVSS

Variable light chain, mouse (SEQ ID NO:8)

DIQMTQTTSS LSASLGDRVT ISCSASQDIN NYLNWYQQKP DGTVKLLIYY
TSSLHSGVPS RFSGSGSGTD YSLTISNLEP EDFATYYCQQ FSNLPWTFGG
GTKLEIKRAD

Variable heavy chain, mouse (SEQ ID NO: 9)

EVQLVETGGG LVQPKGSLKL SCAASGFTFN TNAMNWVRQA PGKGLEWVAR
IRSKSNNYAT YYADSVKDRF TLSRDDSQSM LYLQMNNLKT EDTAMYYCVR
DRGWGAMDYW GQGTTVTVS

Variable heavy chain, mouse (SEQ ID NO: 10)

EVQLVESGGG LVQPKGSLKL SCAASGFTFN TNAMNWVRQA PGKGLEWVAR
IRSKSNNYAT YYADSVKDRF TLSRDDSQSM LYLQMNNLKT EDTAMYYCVR
DRGWGAMDYW GQGTTVTVS

Images

Figure 1

Variable light chain, humanised (SEQ ID NO: 13)

DIQMTQSPSS LSASVGDRVT ITCSASQDIN NYLNWYQQKPGKAPKLLIYY TSSLHSGVPS RFSGSGSGTD FTLTISSLQP EDFATYYCQQ FSNLPWTFGGGTKLEIK

Variable heavy chain, humanised (SEQ ID NO: 14)

EVQLVESGGG LVKPGGSLRL SCAASGFTFN TNAMNWVRQAPGKGLEWVAR IRSKSNNYAT YYADSVKDRF TLSRDDSKNT LYLQMNSLKT EDTAVYYCTRDRGWGAMDYW GQGTTVTVSS

Variable heavy chain, humanised (SEQ ID NO: 15)

EVQLVESGGG LVKPGGSLRL SCAASGFTFN TNAMNWVRQAPGKGLEWVAR IRSKSNNYAT YYADSVKDRF TISRDDSKNT LYLQMNSLKT EDTAVYYCTRDRGWGAMDYW GQGTTVTVSS

Variable light chain, mouse (SEQ ID NO:8)

DIQMTQTTSS LSASLGDRVT ISCSASQDIN NYLNWYQQKP DGTVKLLIYY TSSLHSGVPS RFSGSGSGTD YSLTISNLEP EDFATYYCQQ FSNLPWTFGG GTKLEIKRAD

Variable heavy chain, mouse (SEQ ID NO: 9)

EVQLVETGGG LVQPKGSLKL SCAASGFTFN TNAMNWVRQA PGKGLEWVAR IRSKSNNYAT YYADSVKDRF TLSRDDSQSM LYLQMNNLKT EDTAMYYCVR DRGWGAMDYW GQGTTVTVS

Variable heavy chain, mouse (SEQ ID NO: 10)

EVQLVESGGG LVQPKGSLKL SCAASGFTFN TNAMNWVRQA PGKGLEWVAR IRSKSNNYAT YYADSVKDRF TLSRDDSQSM LYLQMNNLKT EDTAMYYCVR DRGWGAMDYW GQGTTVTVS

Fusion proteins forming trimers
EP2382236 A1

Current assignees

APOGENIX*

Inventors

HILL OLIVER
BRANSCHÄDEL MARCUS
GIEFFERS CHRISTIAN
THIEMANN MEINOLF

Priority data including date

2009EP-0778928 2009-01-09
2009WO-EP50233 2009-01-09
2011US-13143531 2011-09-06
2014EP-0175762 2009-01-09
2014US-14160240 2014-01-21
2014US-14322852 2014-07-02

IPC - International classification

A61K-038/00	A61K-039/395	A61P-003/00
A61P-031/00	A61P-035/00	A61P-037/02
A61P-037/06	C07K-001/00	C07K-007/06
C07K-014/00	C07K-014/47	C07K-014/52
C07K-014/525*	C07K-014/705	C07K-016/00
C07K-017/00	C07K-019/00	C12N-015/09
C12N-015/62	C12P-021/08	

CPC - Cooperative classification

C07K-007/06	C07K-014/00	C07K-014/47/26
C07K-014/525*	C07K-014/705/75	C07K-016/00
C07K-2319/00	C07K-2319/21	C07K-2319/22
C07K-2319/70	C12N-015/62	

PCL - US patent classification

PCLO:	530387300*	530351000*	530387300*
PCLX:	530389200	530396000	

Family

WO2010078966	A1	2010-07-15	EP2829550	A3	2015-04-29	
EP2382236	A1	2011-11-02	US20150126710	A1	2015-05-07	
US20120041181	A1	2012-02-16	JP5844158	B2	2016-01-13	
JP2012514616	A	2012-06-28	EP2382236	B1	2016-08-17	
US8664366	B2	2014-03-04	US9469681	B2	2016-10-18	
US20140171622	A1	2014-06-19	EP2829550	B1	2016-11-16	
EP2829550	A2	2015-01-28	ES2593049	T3	2016-12-05	

(EP2829550)

The present invention refers to fusion proteins comprising a neck region and carbohydrate recognition domain of a collectin trimerization domain, a linker element and an effector polypeptide.Further the invention refers to a nucleic acid encoding the said fusion protein.The fusion proteins, the nucleic acid, and the cell are suitable as pharmaceutical composition or for therapeutic, diagnostic and/or research applications as described herein.



Images


SEC of affinity purified CD95L-ASPD
mAU
600
500
400
300
200
100
0
11.92
9.85
19.83
A1
A2
A3
A4
A5
A6
A7
A8
A9
A10
A11
6.0
8.0
10.0
12.0
14.0
16.0
18.0
20.0
22.0
ml
A1 – A11

Industrial truck comprising a system for detecting spinning or locking of the drive wheel
EP2181877 A1

Current assignees

APOGENIX

BT PRODUCTS*

GTE PRODUCTS

Inventors

ARNSBY MATTIAS

Priority data including date

2008EP-0168033 2008-10-31

IPC - International classification

B60K-028/16*	B60L-003/00	B60L-007/26
B60L-015/20	B60T-008/172	B60T-008/175
B60T-008/176	B66F-009/075	B66F-009/24
G06F-019/00	H02P-007/00	H02P-029/00

CPC - Cooperative classification

B60L-003/00/76	B60L-003/10/2	B60L-007/26
B60L-011/18	B60L-015/20	B60T-008/175*
B60Y-2200/15	B66F-009/24	Y02T-010/645
Y02T-010/7005	Y02T-010/72	Y02T-010/7275

PCL - US patent classification

PCLO: 701022000*

PCLX: 318434000

Family

CA2684051	A1	2010-04-30	EP2181877	B1	2012-12-19	
EP2181877	A1	2010-05-05	AU2009230755	B2	2014-04-24	
US20100114415	A1	2010-05-06	CN101722861	B	2014-08-06	
AU2009230755	A1	2010-05-20	CA2684051	C	2016-12-13	
CN101722861	A	2010-06-09				

(EP2181877)

An industrial fork lift truck comprising an electric motor (3), a motor controller (2) for controlling the electric motor (3) and a truck computer (1) for controlling the motor controller (2), said truck computer (1) comprising a detection system (5) for detecting spinning and/or locking of the drive wheel of the truck characterized in that the detection system (5) is arranged to receive a signal corresponding to the momentary torque current of the motor (3); and further comprising: -a calculation unit (12) for calculating the theoretical torque current of the motor (3); -a comparison unit (13) for comparing the theoretical torque current of the motor (3) and the momentary torque current of the motor (3), wherein the truck computer is arranged to reduce the acceleration or the deceleration of the truck if there is a difference between the theoretical torque current of the motor (3) and the momentary torque current of the motor (3).



Images



Methods and compositions for preventing radiation-induced pneumonitis
US20090196868 A1

Current assignees

APOGENIX*

Inventors

BELKA CLAUS

HERBST JOERG

Priority data including date

2007US-60970336 2007-09-06

2008US-12205250 2008-09-05

2010US-12943692 2010-11-10

IPC - International classification

A61K-038/00	A61K-038/17	A61K-039/395*
A61P-011/00	A61P-029/00	G01N-033/53

CPC - Cooperative classification

A61K-038/17/7	A61K-2039/505	C07K-016/28/75*
C07K-016/28/78		

PCL - US patent classification

PCLO:	514001100*	424133100*	
PCLX:	424172100	435007100	435007200
436501000	514021200		

Family

US20090196868	A1	2009-08-06		US20110171212	A1	2011-07-14

(US20110171212)

Disclosed are methods of minimizing the risk for a patient of developing pneumonitis during radiotherapy for a thorax-associated neoplasm and compositions for use in such methods.A preferred composition comprises a CD95/CD95L inhibitor.Further disclosed is a method of increasing the radiation dose administered to a patient during radiotherapy for a thorax-associated neoplasm.



Images



FIG. 1A

Il-4 fc fusion proteins
WO2008101671 A2

Current assignees

APOGENIX*

Inventors

HILL OLIVER

GIEFFERS CHRISTIAN

THIEMANN MEINOLF

Priority data including date

2007EP-0003443 2007-02-19

IPC - International classification

C07K-014/54 C07K-019/00* C12N-015/62

CPC - Cooperative classification

A61K-038/00 A61K-047/6813 A61K-047/6835

C07K-014/54/06* C07K-2319/30

Family

WO2008101671	A2	2008-08-28		WO2008101671	A9	2009-02-19
WO2008101671	A3	2008-12-11				

(WO2008101671)
The invention relates to fusion proteins comprising at least one IL-4 polypeptide domain and a constant immunoglobulin domain.

Human il-4 muteins in combination with chemotherapeutics or pro-apoptotic agents in cancer therapy
EP2049147 A2

Current assignees
APOGENIX*

Inventors
HOEGER THOMAS
GAMER JUERGEN

Priority data including date
2006EP-0014080 2006-07-06
2006EP-0026609 2006-12-21
2007EP-0785931 2007-07-06
2007WO-EP06026 2007-07-06

IPC - International classification
A61K-038/20* A61K-045/06 A61P-035/00

CPC - Cooperative classification
A61K-031/337 A61K-033/24 A61K-038/20/26
A61K-045/06*

PCL - US patent classification
PCLO: 424085200*

Family

WO2008003514	A2	2008-01-10		WO2008003514	A3	2008-06-12
CA2656135	A1	2008-01-10		EP2049147	A2	2009-04-22
AU2007271349	A1	2008-01-10		US20100086515	A1	2010-04-08

(EP2049147)
The present invention relates to the use of a combination of human interleukin-4 muteins and chemotherapeutic or pro-apoptotic agents for the prevention and/or treatment of cancer disease.



Figure 1

Images



Figure 1

Trimeric death ligands with enhanced activity (tenascin)
EP2009022 A1

Current assignees
APOGENIX*

Inventors
PFIZENMAIER KLAUS
WAJANT HARALD
HILL OLIVER
BRANSCHAEDEL MARCUS

Priority data including date
2007EP-0012523 2007-06-26

IPC - International classification

A61K-047/48	C07K-014/525*	C07K-014/705
C07K-014/715	C12N-015/62	

CPC - Cooperative classification

A61K-047/6813	A61K-047/6849	C07K-014/705/75*
C07K-2317/622	C07K-2319/01	C07K-2319/30
C07K-2319/32		

Family

WO2009000538	A1	2008-12-31		EP2009022	A1	2008-12-31

(EP2009022)
The present invention refers to a fusion protein comprising a TNF-superfamily (TNFSF) cytokine or a receptor binding domain thereof fused to a tenascin (TNC) trimerization domain, to a nucleic acid molecule encoding the fusion protein, and to a cell comprising the nucleic acid molecule.The fusion protein is present as a trimeric complex or as an oligomer thereof.The fusion protein, the nucleic acid, and the cell is suitable as pharmaceutical composition or for therapeutic, diagnostic and/or research applications.



Figure 1

Images



Figure 1

Expressão diferencial de citocina em câncer humano
BR200713484 A2

Current assignees

APOGENIX*

Inventors

STASSI GIORGIO
GIEFFERS CHRISTIAN
HILL OLIVER
THIEMANN MEINOLF
TODARO MATILDE

Priority data including date

2006EP-0012754 2006-06-21
2006EP-0127545 2006-06-21
2007EP-0764767 2007-06-21
2007WO-EP05480 2007-06-21

IPC - International classification

A61K-031/282	A61K-033/24	A61K-038/00
A61K-039/395	A61K-045/06	A61P-035/00
C07H-021/04	C07K-002/00	C07K-014/715
C07K-019/00	C12N-015/09	C12Q-001/68
G01N-033/574*		

CPC - Cooperative classification

G01N-033/574/84* G01N-033/68/63

PCL - US patent classification

PCLO: 424174100*

PCLX: 435006130 435007230 530300000 536023500

Family

WO2007147600	A2	2007-12-27		JP2010514409	A	2010-05-06
CA2656379	A1	2007-12-27		RU2009101783	A	2010-07-27
AU2007263265	A1	2007-12-27		EP2041576	B1	2011-08-10
WO2007147600	A3	2008-04-10		AT520032	T	2011-08-15
EP2041576	A2	2009-04-01		DK2041576	T3	2011-12-05
IN0300/KOLNP/2009	A	2009-05-08		ES2371287	T3	2011-12-29
CN101529253	A	2009-09-09		BRPI0713484	A2	2012-11-06
US20090324616	A1	2009-12-31				

(BR200713484)
EXPRESSãO DIFERENCIAL DE CITOCINA EM CáNCER HUMANO.A presente invenção refere-se a um processo para diagnóstico de um tipo de câncer, pelo que a expressão e citocinas antiapoptóticas é determinadas nas células de tumor.O diagnóstico diferencial da presente invenção é usado para classificar distúrbios de tumor e para recomendar o tratamento requerido e para monitorar o progresso e resposta ao tratamento.

Images

Antibody specific for human il-4 for the treament of cancer
EP2004691 A1

Current assignees

APOGENIX*

Inventors

HOEGER THOMAS

GAMER JUERGEN

STASSI GIORGIO

TODARO MATILDE

Priority data including date

2006EP-0005894 2006-03-22

2007EP-0723455 2007-03-21

2007WO-EP02497 2007-03-21

IPC - International classification

A61K-039/395 A61P-035/00 C07K-016/24*

CPC - Cooperative classification

A61K-039/395/5 C07K-016/24/7*

PCL - US patent classification

PCLO: 424132100*

PCLX: 424133100 424135100 424136100 424145100 424158100 530387300 530388230 530389200

Family

WO2007107349	A1	2007-09-27		EP2004691	A1	2008-12-24
CA2646626	A1	2007-09-27		US20100297110	A1	2010-11-25
AU2007228943	A1	2007-09-27		AU2007228943	B2	2012-03-22

(EP2004691)

The present invention relates to the use of an antibody or an antigen-binding fragment thereof with specific binding activity for human interleukin-4 for the prevention and/or treatment of cancer.

Figure 1



Images

Figure 1

Murine Antibody 3B9 Light Chain
Native Signal Sequence and Variable Region

Amino Acid Sequence SEQ ID NO: 7

```
ATG GAG ACA GAC ACA ATC CTG CTA TGG GTG CTG CTG CTC      39
Met Glu Thr Asp Thr Ile Leu Leu Trp Val Leu Leu Leu
 1               5                  10

TGG GTT CCA GGC TCC ACT GGT GAC ATT GTG CTG ACC CAA      78
Trp Val Pro Gly Ser Thr Gly Asp Ile Val Leu Thr Gln
     15                  20                  25

TCT CCA GCT TCT TTG GCT GTG TCT CTA GGG CAG AGG GCC     117
Ser Pro Ala Ser Leu Ala Val Ser Leu Gly Gln Arg Ala
            30                  35

ACC ATC TCC TGC AAG GCC AGC CAA AGT GTT GAT TAT GAT     156
Thr Ile Ser Cys Lys Ala Ser Gln Ser Val Asp Tyr Asp
 40                  45                  50

GGT GAT AGT TAT ATG AAC TGG TAC CAA CAG AAA CCA GGA     195
Gly Asp Ser Tyr Met Asn Trp Tyr Gln Gln Lys Pro Gly
         55                  60                  65

CAG CCA CCC AAA CTC CTC ATC TAT GCT GCA TCC AAT CTA     234
Gln Pro Pro Lys Leu Leu Ile Tyr Ala Ala Ser Asn Leu
                70                  75

GAA TCT GGG ATC CCA GCC AGG TTT AGT GGC AGT GGG TCT     273
Glu Ser Gly Ile Pro Ala Arg Phe Ser Gly Ser Gly Ser
     80                  85                  90

GGG ACA GAC TTC ACC CTC AAC ATC CAT CCT GTG GAG GAG     312
Gly Thr Asp Phe Thr Leu Asn Ile His Pro Val Glu Glu
            95                  100

GAG GAT GCT GCA ACC TAT TAC TGT CAG CAA AGT AAT GAG     351
Glu Asp Ala Ala Thr Tyr Tyr Cys Gln Gln Ser Asn Glu
105                 110                 115

GAT CCT CCG ACG TTC GGT GGA GGC ACC AAG CTG GAA ATC     390
Asp Pro Pro Thr Phe Gly Gly Gly Thr Lys Leu Glu Ile
        120                 125                 130

AAA CGG                                            396
Lys Arg
```

Tnf superfamily fusion proteins
EP1894940 A1

Current assignees

APOGENIX*

Inventors

HILL OLIVER

GIEFFFERS CHRISTIAN

THIEMANN MEINOLF

Priority data including date

2006EP-0017891 2006-08-28

2007CA-2661599 2007-08-28

2007EP-0801940 2007-08-28

2007WO-EP07517 2007-08-28

2009US-12439486 2009-02-27

2012US-13403826 2012-02-23

IPC - International classification

A01H-001/00	A01H-005/00	A01K-067/027
A61K-035/12	A61K-035/74	A61K-038/00
A61K-038/16	A61K-038/19	A61K-039/00
A61K-048/00	A61P-003/00	A61P-019/02
A61P-025/00	A61P-025/28	A61P-029/00
A61P-031/00	A61P-035/00	A61P-037/04
C07K-014/005	C07K-014/01*	C07K-014/525
C07K-014/705	C07K-019/00*	C12N-001/15
C12N-001/19	C12N-001/21	C12N-005/10
C12N-015/00	C12N-015/09	C12N-015/62
C12Q-001/68	G01N-033/50	

CPC - Cooperative classification

C07K-014/525*	C07K-014/705/75	C07K-2319/73

PCL - US patent classification

PCLO:	424192100*	424192100*	
PCLX:	435455000	514001400	530350000
530351000	536023400		

Family

EP1894940	A1	2008-03-05	EP2069392	B1	2011-04-13	
CA2860945	A1	2008-03-06	AT505481	T	2011-04-15	
WO2008025516	A2	2008-03-06	DE602007013920	D1	2011-05-26	
CA2661599	A1	2008-03-06	US8147843	B2	2012-04-03	
AU2007291490	A1	2008-03-06	US20120148527	A1	2012-06-14	
WO2008025516	A3	2008-04-17	JP5274464	B2	2013-08-28	
EP2069392	A2	2009-06-17	US8580273	B2	2013-11-12	
JP2010501191	A	2010-01-21	CA2661599	C	2015-06-09	
US20110027218	A1	2011-02-03	CA2860945	C	2015-12-29	

(EP2069392)

The present invention refers to fusion proteins comprising a TNF superfamily (TNFSF) cytokine or a receptor binding domain thereof fused to a trimerization domain and a nucleic acid molecule encoding the fusion protein.The fusion protein is present as a trimeric complex or as an oligomer thereof and is suitable for therapeutic, diagnostic and/or research applications.

Figure 1A



Figure 1B



Images

Figure 1A



Figure 1B



Method for the purification and amplification of tumoral stem cells
EP1805299 A1

Current assignees

APOGENIX*

UNIVERSITA DEGLI STUDI DI PALERMO

Inventors

STASSI GIORGIO

TODARO MATILDE

Priority data including date

2004IT-RM00438 2004-09-15

2005EP-0794564 2005-09-14

2005WO-IT00523 2005-09-14

IPC - International classification

A61K-038/20 A61K-039/395 A61P-035/00

C12N-005/095*

CPC - Cooperative classification

C12N-005/0695* C12N-2500/25 C12N-2501/11

C12N-2501/115 C12N-2501/392 C12N-2501/91

PCL - US patent classification

PCLO: 424085200*

PCLX: 424174100 435375000 435381000

Family

ITRM20040438	A1	2004-12-15		US20070292389	A1	2007-12-20
WO2006030473	A1	2006-03-23		EP2006374	A2	2008-12-24
CA2580645	A1	2006-03-23		EP2006374	A3	2009-05-27
EP1805299	A1	2007-07-11				

(EP2006374)

The invention concerns a method for the purification and amplification in the undifferentiated state of tumoral stem cells from solid tumours which are most resistant to conventional therapies, aiming at devising new tumour markers and therapeutic targets both for early diagnosis and for targeted therapeutic strategies.

Images

Proteínas de fusão de fc melhoradas
EP1606319 A2

Current assignees

APOGENIX
APOGENIX BIOTECHNOLOGY
DEUTSCHES KREBSFORCHUNGSZENTRUM STIFTUNG DES OEFFENTLICHEN RECHTS
DKFZ DEUTSCHES KREBSFORSCHUNGSZENTRUM
MEDINNOVA GES FUR MEDIZINISCHE
MEDINNOVA GESELLSCHAFT FÜR MEDIZINISCHE INNOVATIONEN AUS AKADEMISCHER FORSCHUNG MBH

Inventors

LUDWIG STEPHAN
PLESCHKA STEPHAN
WALCZAK HENNING
PLANZ OLIVER
HIRT ULRICH

Priority data including date

2003EP-0006949 2003-03-26
2004EP-0723552 2004-03-26
2004EP-0723556 2004-03-26
2004WO-EP03239 2004-03-26
2004WO-EP03245 2004-03-26
2007US-12551004 2007-04-12
2011US-13213345 2011-08-19

IPC - International classification

A01K-067/027	A61K-031/7088	A61K-031/7105
A61K-038/00	A61K-038/16	A61K-038/17
A61K-038/43	A61K-039/395	A61K-045/00
A61K-048/00	A61P-001/16	A61P-009/00
A61P-009/10	A61P-013/12	A61P-025/00
A61P-029/00	A61P-031/04	A61P-031/12*
A61P-031/16	A61P-031/18	A61P-037/02
A61P-037/06	A61P-043/00	C07H-021/00
C07H-021/04	C07K-014/00	C07K-014/47
C07K-014/475	C07K-014/52	C07K-014/525
C07K-014/54	C07K-014/705	C07K-014/715
C07K-016/28	C07K-019/00*	C12N-001/19
C12N-001/21	C12N-005/10	C12N-005/22
C12N-015/09	C12N-015/63	C12P-021/00
C12Q-001/02	G01N-033/15	G01N-033/50

CPC - Cooperative classification

A61K-2039/505	C07K-014/705/75	C07K-014/705/78
C07K-016/28/75*	C07K-016/28/78	C07K-2319/30

PCL - US patent classification

PCLO:	424134100*	424192100*	
PCLX:	435069700	435252330	435254200
435320100	435325000	435348000	435366000
435419000	514021200	514021300	514044000R
530350000	530387300	536023400	

Family

WO2004085479	A2	2004-10-07	EP1606318	B1	2009-08-05	
WO2004085478	A2	2004-10-07	AT438662	T	2009-08-15	
CA2520254	A1	2004-10-07	DE602004022390	D1	2009-09-17	
CA2520138	A1	2004-10-07	ES2327409	T3	2009-10-29	
AU2004224123	A1	2004-10-07	DK1606318	T3	2009-11-02	
AU2004224122	A1	2004-10-07	PT1606318	E	2009-11-10	
WO2004085479	A3	2004-11-25	SI1606318	T1	2009-12-31	
WO2004085478	A3	2005-01-06	JP4741464	B2	2011-08-03	
EP1606319	A2	2005-12-21	US8007813	B2	2011-08-30	
EP1606318	A2	2005-12-21	US20110305697	A1	2011-12-15	
JP2007524365	A	2007-08-30	CY1109536	T1	2014-08-13	
US20070269449	A1	2007-11-22	CA2520138	C	2017-05-23	
JP2007533595	A	2007-11-22				

(EP1606319)

Figure 1

CD95

>sp|P25445|TNR6_HUMAN Tumor necrosis factor receptor superfamily member 6

The present invention relates to the use of inhibitors of the TRAIL ligand/TRAIL receptor system for the manufacture of a medicament for the prevention or treatment of viral diseases, particularly for the prevention or treatment of influenza or Borna disease virus infections.

Images

Figure 1

CD95

>sp|P25445|TNR6_HUMAN Tumor necrosis factor receptor superfamily member 6 precursor (FASL receptor) (Apoptosis-mediating surface antigen FAS) (Apo-1 antigen) (CD95) - Homo sapiens (Human).

```
1                                                                    60
MLGIWTLLPL VLTSVARLSS KSVNAQVTDI NSKGLELRKT VTTVETQNLE GLHHDGQFCH
61                                                                  120
KPCPPGERKA RDCTVNGDEP DCVPCQEGKE YTDKAHFSSK CRRCRLCDEG HGLEVEINCT
121                                                                 180
RTQNTKCRCK PNFFCNSTVC EHCDPCTKCE HGIIKECTLT SNTKCKEEGS RSNLGWLCLL
181                                                                 240
LLPIPLIVWV KRKEVQKTCR KHRKENQGSH ESPTLNPETV AINLSDVDLS KYITTIAGVM
241                                                                 300
TLSQVKGFVR KNGVNEAKID EIKNDNVQDT AEQKVQLLRN WHQLHGKKEA YDTLIKDLKK
301                                335
ANLCTLAEKI QTIILKDITS DSENSNFRNE IQSLV
```

AA 1-16 Signal peptide (potential)
AA 17-173 extracellular domain (potential)
AA 47-83 CRD1
AA 84-127 CRD2
AA 128-166 CRD3
AA 174-190 transmembrane (potential)
AA 191-335 cytoplasmic (potential)